Last ¥3,555 JPY
Change Today +60.00 / 1.72%
Volume 1.4M
4507 On Other Exchanges
As of 1:00 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

shionogi & co ltd (4507) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/30/15 - ¥3,620
52 Week Low
04/11/14 - ¥1,733
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SHIONOGI & CO LTD (4507)

Related News

No related news articles were found.

shionogi & co ltd (4507) Related Businessweek News

No Related Businessweek News Found

shionogi & co ltd (4507) Details

Shionogi & Co., Ltd. manufactures and distributes pharmaceuticals, diagnostic reagents, medical devices, etc. primarily in Asia, North America, and Europe. Its principal products include various prescription drugs, including Osphena to treat postmenopausal vulvar and vaginal atrophy; Crestor tablets for the treatment of hyperlipidemia; Irbetan tablets for the treatment of hypertension; Cymbalta capsules to treat depression, depressive condition, and diabetic neuropathic pain; cancer pain analgesics, such as OxyContin tablets, OxiNorm powders, and OxiFast injections; Tivicay tablets for HIV treatment; Finibax and Finibax solution kit for intravenous drip infusion; Differin gel for the treatment of topical acne vulgaris; Pirespa tablets used to treat idiopathic pulmonary fibrosis; and Rapiacta, an antiviral drug for the treatment of influenza. The company also offers over the counter drugs comprising Popon series of multiple vitamin supplements; and Sedes, a line of analgesic antipyretics. In addition, it provides diagnostics reagents, such as Shionospot Reader and Shionospot BNP, a human brain natriuretic peptide kit; Allerport TARC, a thymus and activation-regulated chemokine kit; Allerport HRT, a reagent for identifying allergens; Brightpoc Flu, an influenza virus diagnostic kit; and Checkart Reader for measuring hemoglobin A1c and glucose levels in blood for use in diagnosing diabetes and other related clinical conditions. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

6,165 Employees
Last Reported Date: 06/25/14
Founded in 1878

shionogi & co ltd (4507) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

shionogi & co ltd (4507) Key Developments

Shionogi & Co., Ltd. Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended September 30, 2014; Provides Earnings Guidance for the Year Ending March 31, 2015; Declares Interim Dividend for the Period Ended September 30, 2014, Payable on Dec. 1, 2014; Provides Dividend Guidance for the Year Ending March 31, 2015

Shionogi & Co., Ltd. announced consolidated earnings results for the second quarter and six months ended September 30, 2014. For the quarter, the company reported posted a 6% year on year drop in net sales, after a solid performance by its strategic pharmaceutical products failed to offset a drug price revision in Japan in April. Net sales were JPY 71.4 billion (USD 660.5 million) versus JPY 67.1 billion a year earlier. Net loss was JPY 600 million compared to net income of JPY 10.3 billion in the year-ago period. For the six months, the company reported net sales of JPY 129,742 million against JPY 138,715 million a year ago. Operating income was JPY 22,719 million against JPY 27,946 million a year ago. Ordinary income was JPY 31,415 million against JPY 27,314 million a year ago. Net income was JPY 9,710 million or JPY 28.98 per diluted share against JPY 21,086 million or JPY 62.93 per diluted share a year ago. Income before income taxes and minority interests was JPY 31,661 million against JPY 31,621 million a year ago. Net cash provided by operating activities was JPY 22,346 million against JPY 40,707 million a year ago. Purchase of property, plant and equipment was JPY 6,592 million against JPY 3,588 million a year ago. Purchase of intangible assets was JPY 1,482 million against JPY 6,952 million a year ago. For the year ending March 31, 2015, the company forecasted a 5.6% drop in net sales to JPY 273.5 billion, and a 26.1% fall in net income to JPY 30 billion or JPY 89.58 per share. Operating income to be JPY 49,500 million and ordinary income to be JPY 58,000 million. For the period ended September 30, 2014, the company declared a dividend of JPY 24.0 per share, payable on Dec. 1, 2014. For the year ending March 31, 2015, the company provides year-end dividend guidance of JPY 24.0.

Shionogi & Co., Ltd., Q2 2015 Earnings Call, Oct 29, 2014

Shionogi & Co., Ltd., Q2 2015 Earnings Call, Oct 29, 2014

Shionogi & Co., Ltd. Revises Earnings Guidance for the First Half Ended September 30, 2014

Shionogi & Co., Ltd. revised earnings guidance for the first half ended September 30, 2014. For the period, the company expects net income to be JPY 9.5 billion or JPY 28.37 per share, compared to the previous forecast of JPY 16 billion, or JPY 47.78 per share, for the same period ending September 30, 2014. The company expects operating income to be JPY 22.5 billion compared to the previous guidance of JPY 18.5 billion. The company expects ordinary income to be JPY 31 billion, compared to the previous guidance of JPY 24 billion.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4507:JP ¥3,555.00 JPY +60.00

4507 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $45.26 USD +1.85
Pfizer Inc $31.83 USD -0.12
Shire PLC 4,930 GBp +32.00
Theravance Inc $11.32 USD +0.38
View Industry Companies

Industry Analysis


Industry Average

Valuation 4507 Industry Range
Price/Earnings 36.2x
Price/Sales 3.8x
Price/Book 2.3x
Price/Cash Flow 37.9x
TEV/Sales 3.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIONOGI & CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at